SGT Stock Overview
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SGT from our risk checks.
Seagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$208.60 |
| 52 Week High | US$212.00 |
| 52 Week Low | US$116.78 |
| Beta | 0.32 |
| 1 Month Change | 6.27% |
| 3 Month Change | 6.92% |
| 1 Year Change | 74.04% |
| 3 Year Change | 28.86% |
| 5 Year Change | 318.88% |
| Change since IPO | 6,694.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| SGT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.4% | -1.2% | -0.8% |
| 1Y | 74.0% | -15.8% | 1.0% |
Return vs Industry: SGT exceeded the German Biotechs industry which returned -23.2% over the past year.
Return vs Market: SGT exceeded the German Market which returned 4.8% over the past year.
Price Volatility
| SGT volatility | |
|---|---|
| SGT Average Weekly Movement | 2.0% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SGT has not had significant price volatility in the past 3 months.
Volatility Over Time: SGT's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3,256 | David Epstein | www.seagen.com |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases.
Seagen Inc. Fundamentals Summary
| SGT fundamental statistics | |
|---|---|
| Market cap | €39.61b |
| Earnings (TTM) | -€688.56m |
| Revenue (TTM) | €2.11b |
18.8x
P/S Ratio-57.5x
P/E RatioIs SGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGT income statement (TTM) | |
|---|---|
| Revenue | US$2.30b |
| Cost of Revenue | US$2.13b |
| Gross Profit | US$171.59m |
| Other Expenses | US$921.81m |
| Earnings | -US$750.22m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.98 |
| Gross Margin | 7.46% |
| Net Profit Margin | -32.61% |
| Debt/Equity Ratio | 0% |
How did SGT perform over the long term?
See historical performance and comparison